(CRBN) Corbion - Ratings and Ratios
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0010583399
Lactic Acid, Food Preservatives, Algae Ingredients, Bioplastics, Biochemicals
Dividends
| Dividend Yield | 3.36% |
| Yield on Cost 5y | 1.56% |
| Yield CAGR 5y | 3.39% |
| Payout Consistency | 92.3% |
| Payout Ratio | 57.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 28.9% |
| Value at Risk 5%th | 39.4% |
| Relative Tail Risk | -17.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -17.27 |
| CAGR/Max DD | -0.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.563 |
| Beta | 0.234 |
| Beta Downside | 0.266 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.20% |
| Mean DD | 40.41% |
| Median DD | 43.00% |
Description: CRBN Corbion January 19, 2026
Corbion N.V. (AS: CRBN) is a Dutch specialty-chemicals group that manufactures lactic-acid-based ingredients, food-preservation solutions, functional blends, and algae-derived oils. Its operations are split between the Functional Ingredients & Solutions segment and the Health & Nutrition segment, serving food, personal-care, animal-nutrition, pharmaceutical, medical-device and bioplastic markets through a global network of sales offices and distributors.
Key metrics (FY 2023) show revenue of roughly €1.1 billion with an adjusted EBITDA margin near 12 %, while sales of its biodegradable bioplastics rose ~20 % year-on-year. The lactic-acid market is expanding at a 5-6 % CAGR, driven by EU Green-Deal policies that incentivise low-carbon, renewable feedstocks, and the company’s recent partnership with BRAIN Biotech AG to co-develop novel biobased antimicrobials could unlock additional high-margin growth.
For a deeper, data-rich assessment of Corbion’s valuation and risk profile, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 111.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 5.16 > 1.0 |
| NWC/Revenue: 4.11% < 20% (prev 1.67%; Δ 2.44% < -1%) |
| CFO/TA 0.16 > 3% & CFO 226.3m > Net Income 111.1m |
| Net Debt (404.9m) to EBITDA (300.7m): 1.35 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.1m) vs 12m ago -2.77% < -2% |
| Gross Margin: 23.54% > 18% (prev 0.23%; Δ 2332 % > 0.5%) |
| Asset Turnover: 139.4% > 50% (prev 72.11%; Δ 67.30% > 0%) |
| Interest Coverage Ratio: 4.47 > 6 (EBITDA TTM 300.7m / Interest Expense TTM 45.7m) |
Altman Z'' (< 1.1 .. > 2.6) 3.80
| A: 0.06 (Total Current Assets 514.2m - Total Current Liabilities 423.3m) / Total Assets 1.45b |
| B: 0.47 (Retained Earnings 685.1m / Total Assets 1.45b) |
| C: 0.13 (EBIT TTM 204.2m / Avg Total Assets 1.59b) |
| D: 0.94 (Book Value of Equity 685.1m / Total Liabilities 727.3m) |
| Altman-Z'' Score: 3.80 = AA |
ValueRay F-Score (Strict, 0-100) 67.98
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: -4.83% |
| 3. FCF Margin: -3.35% |
| 4. Debt/Equity: 0.61 |
| 5. Debt/Ebitda: 1.35 |
| 6. ROIC - WACC: 9.85% |
| 7. RoE: 15.36% |
| 8. Revenue Trend: 70.03% |
| 9. EPS Trend: -34.60% |
What is the price of CRBN shares?
As of January 23, 2026, the stock is trading at EUR 19.71 with a total of 140,156 shares traded.
Over the past week, the price has changed by +1.44%, over one month by +8.24%, over three months by +13.60% and over the past year by -10.95%.
Over the past week, the price has changed by +1.44%, over one month by +8.24%, over three months by +13.60% and over the past year by -10.95%.
Is CRBN a buy, sell or hold?
Corbion has no consensus analysts rating.
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.4 | 23.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 19.5 | -1.2% |
CRBN Fundamental Data Overview January 20, 2026
Market Cap USD = 1.32b (1.13b EUR * 1.1673 EUR.USD)
P/E Trailing = 17.4955
P/E Forward = 13.6799
P/S = 0.8707
P/B = 1.5391
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.53b EUR (1.13b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
EV/FCF = -20.70x (Enterprise Value 1.53b / FCF TTM -74.1m)
FCF Yield = -4.83% (FCF TTM -74.1m / Enterprise Value 1.53b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.53b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 6.22% (E(1.13b)/V(1.57b) * Re(6.78%) + D(445.0m)/V(1.57b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 70.03 | Revenue CAGR: 19.49% | SUE: -0.06 | # QB: 0
EPS next Year (2026-12-31): EPS=1.45 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+1.9%
P/E Trailing = 17.4955
P/E Forward = 13.6799
P/S = 0.8707
P/B = 1.5391
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.53b EUR (1.13b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
EV/FCF = -20.70x (Enterprise Value 1.53b / FCF TTM -74.1m)
FCF Yield = -4.83% (FCF TTM -74.1m / Enterprise Value 1.53b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.53b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 6.22% (E(1.13b)/V(1.57b) * Re(6.78%) + D(445.0m)/V(1.57b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 70.03 | Revenue CAGR: 19.49% | SUE: -0.06 | # QB: 0
EPS next Year (2026-12-31): EPS=1.45 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+1.9%